Provigil use skyrockets, with 89% off-label; Pandemic strain's Tamiflu resistance may be increasing;

@FiercePharma: Have generics reached a saturation point? With 84% utilization, maybe. And specialty prices are soaring. Article | Follow @FiercePharma

@EricPFierce: 600,000 bottles of Glenmark's generic Singulair recalled for fishy smell. Recalls for odors not a rarity. Article | Follow @EricPFierce

> The narcolepsy drug Provigil racked up a half-million patients between 2002 and 2009, and 89% of those scripts were written for off-label uses, including depression. Report

> Viral resistance to the Roche ($RHHBY) influenza drug Tamiflu may be increasing in the pandemic H1N1 strain, WHO officials said. Report

> Walgreen and Alliance Boots inked a 10-year deal with drug distributor Amerisource Bergen, allowing them to take up to a 23% stake in the company; the deal squeezes out rival distributor Cardinal Health. Report

> Strides Arcolab unit Agila Biotech agreed to set up a $34.4 million biotech facility in Malaysia. Report

> Ukrainian officials say they want drugmakers to declare their prices during the approvals process. Report

Medical Device News

 @FierceMedDev: FDA sticks Class I tag on Symbios' pump recall. Story | Follow @FierceMedDev

 @MarkHFierce: China's Dehaier Medical Systems will be one to watch in 2013 as it pursues govt. healthcare contracts at home. Story | Follow @MarkHFierce

 @DamianFierce: Third Rock Ventures-backed DC Devices hauled in another $10+ million for its heart failure device. More | Follow @DamianFierce

> NuVasive hit with FDA warning letter over spine device. More

> Johns Hopkins team takes step toward creating migraine blood Dx. Story

Biotech News

 @FierceBiotech: FDA staff review raises big questions about fate of Titan's Probuphine. More | Follow @FierceBiotech

@JohnCFierce: Biopharma's Top R&D Spenders - 2012. Special Report | Follow @JohnCFierce

@RyanMFierce: Fierce's top 5 feats in life sciences 'gamification'. Special Report | Follow @RyanMFierce

> FDA staff review raises big questions about fate of Titan's Probuphine. More

> One foot in biotech graveyard, NeuroSearch is calling it quits. Article

> NPS Pharma goes global with $80M deal to buy back Gattex rights. Story

Biotech Research News

@EmilyMFierce: Not to alarm anyone, but new research suggests that the black plague may still be a threat today. Post | Follow @EmilyMFierce

> Protein points to hormone therapy-resistant prostate cancer. Report

> Stem cell treatment could accelerate diabetic wound healing. Story

> Mount Sinai gets $5M from NIH to study neurological voice condition. Item

> Scripps, Takeda renew pact to find CNS treatments. More

Pharma Manufacturing News

> Claris a buyout candidate as shortages remake injectables biz. Item

> AmerisourceBergen gets Walgreen, Boots biz. Story

> FDA now inspecting 'high risk' compounders. News

> Lilly warehouse thieves followed risk-assessment 'road map.' Report

And Finally... Widespread HIV testing and treatment could boost drug resistance in the virus, experts said. Report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.